Protalix BioTherapeutics Issues 2023 Letter to Stockholders
- Tuesday, January 3, 2023, 7:03
- Finance
- Add a comment
CARMIEL, Israel, Jan. 3, 2023 /PRNewswire/ — Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell…
About the Author
adminasapcorp has written 41525 stories on this site.